Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Ventures L.P. 5Am sold 114,756 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $6.93, for a total transaction of $795,259.08. Following the sale, the insider owned 2,848,310 shares in the company, valued at $19,738,788.30. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Entrada Therapeutics Stock Performance
Shares of TRDA traded up $0.47 during mid-day trading on Monday, hitting $7.26. 500,498 shares of the company’s stock were exchanged, compared to its average volume of 329,656. The company has a market cap of $281.84 million, a price-to-earnings ratio of -1.82 and a beta of -0.26. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $16.45. The stock’s 50-day moving average is $6.83 and its 200-day moving average is $9.84.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The business had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. As a group, equities research analysts anticipate that Entrada Therapeutics, Inc. will post -4.12 EPS for the current year.
Analyst Ratings Changes
View Our Latest Research Report on TRDA
Institutional Investors Weigh In On Entrada Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP grew its stake in shares of Entrada Therapeutics by 4.3% during the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after purchasing an additional 206,911 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Entrada Therapeutics by 735.0% in the third quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company’s stock valued at $776,000 after buying an additional 117,844 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in Entrada Therapeutics during the 3rd quarter worth about $82,000. Finally, IHT Wealth Management LLC purchased a new stake in Entrada Therapeutics during the 2nd quarter worth about $72,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.
Entrada Therapeutics Company Profile
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Read More
- Five stocks we like better than Entrada Therapeutics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
